A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

Study Identifier
M21-406
CT.gov Identifier
NCT05308654
EudraCT Identifier
Not available
EUCTIS ID
2022-501685-22
For general inquiries, please contact

844-663-3742 or [email protected]

Recruitment Complete
Sign up for trial alerts

Study Details

Medical Condition
  • Blood Cancer - Multiple Myeloma
    • Study Drug
  • ABBV-453
  • Dexamethasone
  • Daratumumab
  • Lenalidomide
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Eastern Cooperative Oncology Group (ECOG) performance status \<= 1. * Laboratory values meeting the criteria outlined in the protocol. * Documented diagnosis of multiple myeloma (MM) based on standard International Myeloma Working Group (IMWG) criteria. * Has measurable disease at screening as defined in the protocol. * Locally documented or centrally determined t(11;14) positive status and/or centrally determined BCL2high status. Note: If local testing for t(11;14) is discordant with central testing for t(11;14) status, a detailed review of central and local results for t(11;14) status is required to ensure the participants' safety. * Part 1 and Part 2, Arm 1 Only: Refractory to or intolerant of all established MM therapies that are known to provide clinical benefit and are triple class exposed to a proteasome inhibitors (PI), an Immunomodulatory drugs (IMID), and an anti-CD38 monoclonal antibody in previous line(s) of therapy. * Part 2, Arms 2 and 3 Only: Received 1 to 3 prior lines of therapy, including a PI or an IMiD. * Part 1 only: Permitted to be venetoclax or BCL-2 inhibitor exposed in previous lines of therapy. * Life expectancy \>= 12 weeks.
    Exclusion Criteria:
    * Clinically relevant or significant Electrocardiogram (ECG) abnormalities as outlined in the protocol. * Part 2 only: Previous treatment with venetoclax or BCL-2 inhibitor. * Part 2, Arms 2 and 3 only: Prior daratumumab or other anti-CD38 therapy exposure that meets any of the criteria outlined in the protocol.

    Protocol Summary

    Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in disease activity will be assessed.

    ABBV-453 is an investigational drug being developed for the treatment of R/R MM. Part 1 will be a monotherapy dose escalation phase to determine the best dose of ABBV-453. In Part 2, participants are placed in 1 of 3 groups called treatment arms. Each group receives a different treatment. Approximately 28 to 48 adult participants in Part 1 and 150 to 312 adult participants in Part 2 with R/R MM will be enrolled in the study in approximately 70 sites worldwide.

    In Part 1 and the Japan Cohort, Participants will receive oral ABBV-453 tablets once daily (QD) in 28-day cycles. In Part 2, Arm 1, participants will receive continuous doses of oral ABBV-453 tablets QD in combination with oral dexamethasone tablets once weekly in 28-day cycles. In Part 2, Arm 2, participants will receive continuous doses of oral ABBV-453 tablets QD in combination with subcutaneous injections of daratumumab every 1 to 4 weeks and oral dexamethasone tablets once weekly in, 28-day cycles. In Part 2, Arm 3, participants will receive continuous doses of oral ABBV-453 tablets QD in combination with subcutaneous injections of daratumumab every 1 to 4 weeks, oral lenalidomide capsules QD on Days 1-21, and oral dexamethasone tablets once weekly, in 28-day cycles.

    There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.

    Study Locations

    Location
    Status
    Location
    Stanford University School of Med /ID# 242809
    Stanford, California, United States, 94305-2200
    Status
    Not applicable
    Location
    Sylvester Comprehensive Cancer Center /ID# 243417
    Miami, Florida, United States, 33136-1002
    Status
    Not applicable
    Location
    Tulane University School of Medicine /ID# 244854
    New Orleans, Louisiana, United States, 70112
    Status
    Not applicable
    Location
    American Oncology Partners of Maryland /ID# 244858
    Bethesda, Maryland, United States, 20817
    Status
    Not applicable
    Location
    University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 242754
    Ann Arbor, Michigan, United States, 48109
    Status
    Not applicable
    Location
    Mayo Clinic - Rochester /ID# 242844
    Rochester, Minnesota, United States, 55905-0001
    Status
    Not applicable
    Showing {first} - {last} of {total} Results